FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1798292506> ?p ?o ?g. }

• W1798292506 endingPage "59" @default.
• W1798292506 startingPage "54" @default.
• W1798292506 abstract "Aim: Highly advanced metastatic bone disease with extensive osseous infiltration of neuroendocrine tumours (NET) may preclude patients from treatment with peptide receptor radionuclide therapy (PRRT) in concern about haematotoxicity. This study aims to assess the safety and efficacy of PRRT with 177Lu-octreotate in a patient cohort with this condition. Patients, methods:41 PRRT courses were performed in 11 patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET) and florid bone metastases (severely advanced widespread metastatic bone disease). A mean activity of 6.95 GBq 177Lu-octreotate was administered per treatment cycle, aimed at four courses with standard intervals of 3 months. Haematological parameters were determined prior to each treatment course, in 2–4 weeks intervals between the courses, 8–12 weeks after the last course of PRRT and in 3 monthly intervals thereafter. Toxicity was recorded using Common Terminology Criteria for Adverse Events v3.0. Restaging was performed 3 months after termination of PRRT with CT/MRI and functional imaging (modified MDA criteria). Results: Significant (grade III-IV), reversible haematotoxicity occurred in 4 (35%) patients and after 10 (24%) administrations. It either resolved spontaneously (1 patient) or was controlled by supportive measures (3 patients), such as blood transfusions (3 patients) or deferral of the subsequent therapy cycle (1 patient). Patients returned to baseline blood values within up to 23 months after termination of PRRT. The observed treatment response of bone metastases consisted of a partial response in 2, a minor response in 1, stable disease in 7, and progressive disease in 1 patient. Of the 4 patients with metastatic bone pain, 1 experienced complete and 3 partial resolution of symptoms within 3–10 weeks after commencement of PRRT. Conclusion:These preliminary data indicate that PRRT with 177Lu-octreotate can be safely applied even in florid bone metastases with extensive, severely advanced osseous replacement. The higher myelosuppression rate was not associated with serious complications and should not preclude patients from being treated and potentially experiencing remarkable treatment efficacy despite the very advanced stage." @default.
• W1798292506 created "2016-06-24" @default.
• W1798292506 creator A5009302505 @default.
• W1798292506 creator A5046442863 @default.
• W1798292506 creator A5051737896 @default.
• W1798292506 creator A5054631028 @default.
• W1798292506 creator A5061483313 @default.
• W1798292506 creator A5068961348 @default.
• W1798292506 creator A5072823707 @default.
• W1798292506 creator A5077069685 @default.
• W1798292506 creator A5088751597 @default.
• W1798292506 date "2014-01-01" @default.
• W1798292506 modified "2023-09-24" @default.
• W1798292506 title "Kann die Peptid-Radiorezeptortherapie bei diffuser Knochenmetastasierung noch sicher angewendet werden?" @default.
• W1798292506 cites W1601355692 @default.
• W1798292506 cites W1830895663 @default.
• W1798292506 cites W1973230030 @default.
• W1798292506 cites W1982210666 @default.
• W1798292506 cites W1993872787 @default.
• W1798292506 cites W1995634658 @default.
• W1798292506 cites W2016356824 @default.
• W1798292506 cites W2019607817 @default.
• W1798292506 cites W2020961166 @default.
• W1798292506 cites W2025888580 @default.
• W1798292506 cites W2029425304 @default.
• W1798292506 cites W2063178653 @default.
• W1798292506 cites W2063224036 @default.
• W1798292506 cites W2071433338 @default.
• W1798292506 cites W2074731710 @default.
• W1798292506 cites W2075075102 @default.
• W1798292506 cites W2079633798 @default.
• W1798292506 cites W2092706522 @default.
• W1798292506 cites W2098132980 @default.
• W1798292506 cites W2098468148 @default.
• W1798292506 cites W2102617530 @default.
• W1798292506 cites W2124077899 @default.
• W1798292506 cites W2125366524 @default.
• W1798292506 cites W2125398839 @default.
• W1798292506 cites W2126557384 @default.
• W1798292506 cites W2135926091 @default.
• W1798292506 cites W2144166179 @default.
• W1798292506 cites W2148617171 @default.
• W1798292506 cites W2156664220 @default.
• W1798292506 cites W2306987493 @default.
• W1798292506 cites W2310442715 @default.
• W1798292506 hasPublicationYear "2014" @default.
• W1798292506 type Work @default.
• W1798292506 sameAs 1798292506 @default.
• W1798292506 citedByCount "2" @default.
• W1798292506 countsByYear W17982925062018 @default.
• W1798292506 countsByYear W17982925062020 @default.
• W1798292506 crossrefType "journal-article" @default.
• W1798292506 hasAuthorship W1798292506A5009302505 @default.
• W1798292506 hasAuthorship W1798292506A5046442863 @default.
• W1798292506 hasAuthorship W1798292506A5051737896 @default.
• W1798292506 hasAuthorship W1798292506A5054631028 @default.
• W1798292506 hasAuthorship W1798292506A5061483313 @default.
• W1798292506 hasAuthorship W1798292506A5068961348 @default.
• W1798292506 hasAuthorship W1798292506A5072823707 @default.
• W1798292506 hasAuthorship W1798292506A5077069685 @default.
• W1798292506 hasAuthorship W1798292506A5088751597 @default.
• W1798292506 hasConcept C126322002 @default.
• W1798292506 hasConcept C126838900 @default.
• W1798292506 hasConcept C141071460 @default.
• W1798292506 hasConcept C197934379 @default.
• W1798292506 hasConcept C2777793932 @default.
• W1798292506 hasConcept C2778822529 @default.
• W1798292506 hasConcept C2779066768 @default.
• W1798292506 hasConcept C2779134260 @default.
• W1798292506 hasConcept C2989005 @default.
• W1798292506 hasConcept C2993559085 @default.
• W1798292506 hasConcept C71924100 @default.
• W1798292506 hasConcept C72563966 @default.
• W1798292506 hasConceptScore W1798292506C126322002 @default.
• W1798292506 hasConceptScore W1798292506C126838900 @default.
• W1798292506 hasConceptScore W1798292506C141071460 @default.
• W1798292506 hasConceptScore W1798292506C197934379 @default.
• W1798292506 hasConceptScore W1798292506C2777793932 @default.
• W1798292506 hasConceptScore W1798292506C2778822529 @default.
• W1798292506 hasConceptScore W1798292506C2779066768 @default.
• W1798292506 hasConceptScore W1798292506C2779134260 @default.
• W1798292506 hasConceptScore W1798292506C2989005 @default.
• W1798292506 hasConceptScore W1798292506C2993559085 @default.
• W1798292506 hasConceptScore W1798292506C71924100 @default.
• W1798292506 hasConceptScore W1798292506C72563966 @default.
• W1798292506 hasIssue "2" @default.
• W1798292506 hasLocation W17982925061 @default.
• W1798292506 hasOpenAccess W1798292506 @default.
• W1798292506 hasPrimaryLocation W17982925061 @default.
• W1798292506 hasRelatedWork W1608997557 @default.
• W1798292506 hasRelatedWork W1967665878 @default.
• W1798292506 hasRelatedWork W1969170786 @default.
• W1798292506 hasRelatedWork W1970326135 @default.
• W1798292506 hasRelatedWork W1973230030 @default.
• W1798292506 hasRelatedWork W1982090431 @default.
• W1798292506 hasRelatedWork W2000340774 @default.
• W1798292506 hasRelatedWork W2009629472 @default.
• W1798292506 hasRelatedWork W2018913523 @default.

• next